MAPT and Alzheimer disease: In this dynamic scenario, where the rate of p-tau accumulation changes, and Aβ may show fluctuations in time, as discussed previously, an ideal biomarker should be specific enough for an adequate pre-clinical detection of AD and to track the disease progression.